Eureka Genomics Corp.
This article was originally published in Start Up
Executive Summary
Next-gen sequencing start-up Eureka Genomics says its novel algorithms and data structures are especially effective for the analysis of large sets of short genomic subsequences. The company can analyze sequencing data for non-host genetic material, such as bacteria or viruses. It can also design ultraspecific signature sequences that can be used to detect pathogens or ganisms of interest. In addition to its sequencing service business, Eureka intends to generate novel diagnostics, therapeutic targets and possible vaccines based on microorganisms associated with disease.
You may also be interested in...
Start-Up Previews (05/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. "As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors," features profiles of Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharmaceuticals. Plus these Start-Ups Across Health Care: CardioPhotonics, Eureka Genomics, Invuity and OrthoSensor.
Homology Medicines Inc.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.